Cambridge Antibody Technology and Lonza extend Manufacturing Agreement

20-Jan-2004

Cambridge Antibody Technology and Lonza Group Limited announce the extension of their November 2001 agreement, confirming that Lonza Biologics will manufacture and supply clinical grade antibody drugs to CAT through to the end of 2006.

The agreement, which is effective immediately, will guarantee that CAT and its collaborators have access to Lonza's manufacturing capability at production scale (up to 2,000L) for both ongoing programmes and future projects.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!